

AMPLIRUN® NOVEL INFLUENZA A H1N1 RNA CONTROL

For *in vitro* diagnostic use

MBC082: Purified RNA of influenza A H1N1 virus to be used to control *in vitro* diagnosis techniques based in nucleic acids amplification.

INTRODUCTION:

Influenza viruses are enveloped, helical, single stranded RNA (-) viruses with diameters of 80 to 120 nm. Infection typically causes a febrile respiratory illness accompanied by systemic symptoms.

CHARACTERISTICS:

The lyophilized nucleic acid is included in a thermo-sealed foil pouch containing a silica gel bag. It is necessary to reconstitute it before use (refer to "Preparation of reagents").

Preparation: Grown in MDCK infected cells

Extract preparation: Commercial genomic RNA extraction method.

KIT CONTENTS:

- 1 VIRCELL INAH1N1 RNA CONTROL: 1 vial with lyophilized RNA of influenza A H1N1 virus, (A/California/7/2009 strain), (12500-20000 copies/μl once reconstituted (see Table 1)). RNA quantification has been performed by real-time PCR.
- 2 VIRCELL CONTROL RECONSTITUTION SOLUTION: 500 μl of molecular biology grade water, DNase, RNase free.

Lot number		
Concentration	copies/μl	

Table 1.

Materials required but not supplied:
Additional diagnosis kit.

STORAGE REQUIREMENTS:

Special transport conditions not required. Store the lyophilized vial at 2-8°C inside the foil pouch. Once the pouch is opened, reconstitute the lyophilized vial immediately and store between -70°C and -90°C after reconstitution (temperature indicated on the label).

STABILITY AND HANDLING OF REAGENTS:

Handle reagents in aseptic conditions to avoid microbial contaminations.

Use only the amount of reagent required for the test.

After control resuspension RNA solution should be aliquoted in order to avoid multiple freeze-thaw cycles. The product is stable until the expiry date indicated in the label, if the instructions for use are followed.

VIRCELL, S.L. does not accept responsibility for the mishandling of the reagents included in the kit.

RECOMMENDATIONS AND PRECAUTIONS:

1. This product is for *in vitro* diagnosis use only and for professional qualified staff.
2. Sterile tips with aerosol barrier are essential to prevent contamination.
3. Specimens should be handled as in the case of infectious samples using safety laboratory procedures. Thoroughly clean and disinfect all work surfaces with a freshly prepared solution of 0.5% sodium hypochlorite in deionized or distilled water.
4. In order to perform the test it is essential to have separate working areas.
5. Dispose of unused reagents and waste in accordance with all applicable regulations.
6. The component VIRCELL RNA CONTROL could include genetic material or substances of animal and/or human origin. VIRCELL RNA CONTROL contains influenza A H1N1 virus nucleic acids. VIRCELL RNA CONTROL contains purified nucleic acids obtained from inactivated microorganism, nevertheless, it should be considered potentially infectious and handled with care. No present method can offer complete assurance that these or other infectious agents are absent. All materials should be handled and disposed as of potentially infectious. Observe the local regulations for clinical waste disposal.
7. Dilutions below 1000 copies/μl should be made immediately before use. Freezing of product dilutions containing less than 1000 copies/μl is not recommended as partial RNA degradation might occur.

PREPARATION OF THE REAGENTS:

1. Tear the foil pouch containing VIRCELL RNA CONTROL 1.
2. Centrifuge VIRCELL RNA CONTROL 1 1 minute at 1000 g.
3. Add 50 μl of VIRCELL CONTROL RECONSTITUTION SOLUTION 2 and mix until completely reconstituted. The concentration will be 12500-20000 copies/μl once reconstituted (see Table 1).
4. Shake with vortex for 30 seconds to dissolve and homogenize completely.
5. It is recommended to prepare VIRCELL RNA CONTROL aliquots. In case dilutions were to be prepared use VIRCELL CONTROL RECONSTITUTION SOLUTION 2 for this purpose.

TEST PROCEDURE:

Once nucleic acid is reconstituted, use it according to indications of additional diagnosis kit. Use resuspended VIRCELL CONTROL as an extracted clinical sample adding it directly to amplification reagents.

INTERNAL QUALITY CONTROL:

Each batch is subjected to internal quality control testing before releasing. Quality control analysis is performed by real-time PCR. Final quality control results for each particular lot are available.

INTERPRETATION OF RESULTS AND VALIDATION PROTOCOL FOR USERS:

Refer to indications of additional diagnosis kit.

LIMITATIONS OF METHOD:

1. This reagent is intended to be used with methods of human diagnosis. This test has not been verified with other methods.
2. The user of this kit is advised to read carefully and understand the package insert. Strict adherence to the protocol is necessary to obtain reliable test results.



3. Use of this product should be limited only to personnel trained in molecular techniques.

4. The identity test was carried out with some specific primers according to publicly available sequences of the microorganism. Changes in the sequences of the primers of the reaction may produce a range of different sizes or may not display product amplification.

5. This control does not substitute internal diagnostic kit controls.

6. The quantification was carried out by own brand qPCR against a standard used as a calibrator. Results may vary with the amplification conditions of the end user.

7. AMPLIRUN® has not been designed to be used with a particular diagnostic kit coming from a certain manufacturer. It is used to control amplification of a diagnostic laboratory functioning procedure.

PERFORMANCES:

• IDENTITY TEST

RT-PCR analysis of RNA control: RT-PCR analysis was performed with a specific oligonucleotide pair on purified influenza A H1N1 virus RNA. The reaction produced a fragment of the expected size.

• QUANTIFICATION TEST

A correlation test was performed between microorganism culture and influenza A H1N1 virus extracted RNA. Less than 0.5 log variance was observed between both assays.

• INTRA-ASSAY PRECISION

3 replicas of 5 serial dilutions of 3 different vials of the product were performed by the same operator under identical qPCR conditions.











Less than 5% coefficient of variance was observed between all assays.

• INTER-ASSAY PRECISION

3 different replicas of 5 different serial dilutions of 1 vial of the product were individually amplified by 2 different operators on 3 consecutive days.

Less than 5% coefficient of variance was observed between all assays.

SYMBOLS USED IN LABELS:

	<i>In vitro</i> diagnostic medical device
	Use by (expiration date)
	Store at x-y°C
	Batch code
	Catalogue number
	Consult instructions for use
	Reconstitute in x µl
	Shipment temperature
	Storage temperature
	Do not open until use

BIBLIOGRAPHY:

1. Bustin SA. (2000). Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J Mol Endocrinol.* 25(2):169-193.
2. Bustin SA. (2002). Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. *J Mol Endocrinol.* 29(1):23-39.
3. Freeman WM, Walker SJ, Vrana KE. (1999). Quantitative RT-PCR: pitfalls and potential. *Biotechniques.* 1999 26(1):112-122, 124-125.
4. Larionov A, Krause A, Miller W. (2005). A standard curve based method for relative real time PCR data processing. *BMC Bioinformatics.* 6:62.
5. Pérez-Ruiz M, Navarro-Marí JM, Bautista-Marín MF, Pedrosa-Corral I, Sanbonmatsu-Gámez S, Camacho AG, Rojas J, Ruiz-Ortiz J, Rodríguez-Granger J, Carrillo JA. (2010). Development and preliminary evaluation of a rapid oligochromatographic assay for specific detection of new human influenza A H1N1 virus. *J Clin Microbiol.* 48(5):1801-1805.

For further inquiries please contact:

customerservice@vircell.com

REVISED: 2019-01-15

L-MBC082-EN-01

